Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
Business
9 days ago 378 Views 05 Comment 1.5k Share
Listen to this article
0%
The Food and Drug Administration said Monday that Capricor Therapeutics stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial contrary to the companys cla… [+824 chars]
